Primary sclerosing cholangitis - Revision history

Danbot: Add peer-reviewed reference

2026-03-22T10:09:10Z

Add peer-reviewed reference

← Revisión anterior		Revisión del 10:09 22 mar 2026
Línea 4:		Línea 4:
	==Background==		==Background==

	*Autoimmune disease typically seen in young men		*Autoimmune disease typically seen in young men <ref>Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. N Engl J Med. 2016;375(12):1161-1170. PMID 27653566</ref>
	*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts		*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts
	*Most (80%) cases are associated with [[Special:MyLanguage/inflammatory bowel disease\|inflammatory bowel disease]], typically [[Special:MyLanguage/ulcerative colitis\|ulcerative colitis]], 10% of patients with ulcerative colitis have PSC		*Most (80%) cases are associated with [[Special:MyLanguage/inflammatory bowel disease\|inflammatory bowel disease]], typically [[Special:MyLanguage/ulcerative colitis\|ulcerative colitis]], 10% of patients with ulcerative colitis have PSC

Ostermayer: Prepared the page for translation

2026-01-04T23:54:05Z

Prepared the page for translation

← Revisión anterior		Revisión del 23:54 4 ene 2026
Línea 1:		Línea 1:
			<languages/>
			<translate>

	==Background==		==Background==

	*Autoimmune disease typically seen in young men		*Autoimmune disease typically seen in young men
	*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts		*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts
	*Most (80%) cases are associated with [[inflammatory bowel disease]], typically [[ulcerative colitis]], 10% of patients with ulcerative colitis have PSC		*Most (80%) cases are associated with [[Special:MyLanguage/inflammatory bowel disease\|inflammatory bowel disease]], typically [[Special:MyLanguage/ulcerative colitis\|ulcerative colitis]], 10% of patients with ulcerative colitis have PSC
	*Increased risk of colon cancer in patients with Ulcerative colitis and PSC (more than UC alone) Increased risk of cholangiocarcinoma		*Increased risk of colon cancer in patients with Ulcerative colitis and PSC (more than UC alone) Increased risk of cholangiocarcinoma
	*Prevalence is 1 to 6 per 100,000 in the U.S		*Prevalence is 1 to 6 per 100,000 in the U.S


	==Clinical Features==		==Clinical Features==
	*Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], [[cholangitis]], [[pruritus]], weight loss, or [[fever]]
			*Generally asymptomatic but can present with fatigue, [[Special:MyLanguage/abdominal pain\|abdominal pain]], [[Special:MyLanguage/jaundice\|jaundice]], [[Special:MyLanguage/cholangitis\|cholangitis]], [[Special:MyLanguage/pruritus\|pruritus]], weight loss, or [[Special:MyLanguage/fever\|fever]]
	*Mean age at presentation: 30-40		*Mean age at presentation: 30-40


	==Differential Diagnosis==		==Differential Diagnosis==

	*Autoimmune hepatitis		*Autoimmune hepatitis
	*Primary biliary cirrhosis		*Primary biliary cirrhosis
	*IgG4 related disease		*IgG4 related disease


	==Evaluation==		==Evaluation==
	*[[LFTs]]
			*[[Special:MyLanguage/LFTs\|LFTs]]
	**Alkaline phosphatase is usually elevated with mild elevations in aminotransferases		**Alkaline phosphatase is usually elevated with mild elevations in aminotransferases
	**Bilirubin is typically normal, except when common hepatic duct or common bile duct is involved in late stages of disease		**Bilirubin is typically normal, except when common hepatic duct or common bile duct is involved in late stages of disease
Línea 24:		Línea 34:
	*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease		*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease
	*Consider serum IgG4 levels		*Consider serum IgG4 levels


	==Management==		==Management==

	*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day		*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day
	**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension		**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension
	*Periodic dilation of strictures via ERCP or percutaneous route		*Periodic dilation of strictures via ERCP or percutaneous route
	*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)		*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)


	==Disposition==		==Disposition==
	*Annual Screening for colon cancer in patients with concomitant [[ulcerative colitis]]
			*Annual Screening for colon cancer in patients with concomitant [[Special:MyLanguage/ulcerative colitis\|ulcerative colitis]]


	==See Also==		==See Also==


	==References==		==References==

	*Current Clinical Medicine, 2nd edition by Cleveland Clinic		*Current Clinical Medicine, 2nd edition by Cleveland Clinic

	[[Category:GI]]		[[Category:GI]]
			</translate>

Kfarzam: /* Evaluation */

2022-08-18T17:53:41Z

Evaluation

← Revisión anterior		Revisión del 17:53 18 ago 2022
Línea 23:		Línea 23:
	*Diagnosis made by ERCP or MRCP, which demonstrates strictures or beading of the intrahepatic or extrahepatic bile ducts		*Diagnosis made by ERCP or MRCP, which demonstrates strictures or beading of the intrahepatic or extrahepatic bile ducts
	*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease		*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease
			*Consider serum IgG4 levels

	==Management==		==Management==

Kfarzam: /* Differential Diagnosis */

2022-08-18T17:52:58Z

Differential Diagnosis

← Revisión anterior		Revisión del 17:52 18 ago 2022
Línea 11:		Línea 11:

	==Differential Diagnosis==		==Differential Diagnosis==
	*{{Autoimmune hepatitis}}		*Autoimmune hepatitis
	*{{Primary biliary cirrhosis}}		*Primary biliary cirrhosis
	*{{IgG4 related disease}}		*IgG4 related disease

	==Evaluation==		==Evaluation==

Kfarzam: /* Differential Diagnosis */

2022-08-18T17:52:08Z

Differential Diagnosis

← Revisión anterior		Revisión del 17:52 18 ago 2022
Línea 11:		Línea 11:

	==Differential Diagnosis==		==Differential Diagnosis==
	{{Autoimmune hepatitis}}		*{{Autoimmune hepatitis}}
	{{Primary biliary cirrhosis}}		*{{Primary biliary cirrhosis}}
	{{IgG4 related disease}}		*{{IgG4 related disease}}

	==Evaluation==		==Evaluation==

Kfarzam: /* Differential Diagnosis */

2022-08-18T17:51:08Z

Differential Diagnosis

← Revisión anterior		Revisión del 17:51 18 ago 2022
Línea 11:		Línea 11:

	==Differential Diagnosis==		==Differential Diagnosis==
			{{Autoimmune hepatitis}}
			{{Primary biliary cirrhosis}}
			{{IgG4 related disease}}

	==Evaluation==		==Evaluation==

ClaireLewis at 23:38, 29 September 2019

2019-09-29T23:38:06Z

← Revisión anterior		Revisión del 23:38 29 sep 2019
Línea 7:		Línea 7:

	==Clinical Features==		==Clinical Features==
	*Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], cholangitis, ~~puritis~~, weight loss, or [[fever]]		*Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], [[cholangitis]], [[pruritus]], weight loss, or [[fever]]
	*Mean age at presentation: 30-40		*Mean age at presentation: 30-40

Línea 13:		Línea 13:

	==Evaluation==		==Evaluation==
	*Alkaline phosphatase is usually elevated with mild elevations in aminotransferases		*[[LFTs]]
	*Bilirubin is typically normal, except when common hepatic duct or common bile duct is involved in late stages of disease		**Alkaline phosphatase is usually elevated with mild elevations in aminotransferases
			**Bilirubin is typically normal, except when common hepatic duct or common bile duct is involved in late stages of disease
	*Perinuclear antineutrophil cytoplasmic antibody (pANCA) positive in 2/3rds of cases		*Perinuclear antineutrophil cytoplasmic antibody (pANCA) positive in 2/3rds of cases
	*Cholangiography		*Cholangiography

Mholtz: Text replacement - "==Treatment==" to "==Management=="

2017-12-07T14:40:40Z

Text replacement - "==Treatment==" to "==Management=="

← Revisión anterior		Revisión del 14:40 7 dic 2017
Línea 20:		Línea 20:
	*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease		*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease

	==~~Treatment~~==		==Management==
	*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day		*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day
	**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension		**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension

Neil.m.young: Text replacement - " ==" to "=="

2016-08-03T16:33:19Z

Text replacement - " ==" to "=="

← Revisión anterior		Revisión del 16:33 3 ago 2016
Línea 1:		Línea 1:
	==Background ==		==Background==
	*Autoimmune disease typically seen in young men		*Autoimmune disease typically seen in young men
	*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts		*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts
Línea 6:		Línea 6:
	*Prevalence is 1 to 6 per 100,000 in the U.S		*Prevalence is 1 to 6 per 100,000 in the U.S

	==Clinical Features ==		==Clinical Features==
	*Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], cholangitis, puritis, weight loss, or [[fever]]		*Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], cholangitis, puritis, weight loss, or [[fever]]
	*Mean age at presentation: 30-40		*Mean age at presentation: 30-40
Línea 20:		Línea 20:
	*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease		*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease

	==Treatment ==		==Treatment==
	*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day		*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day
	**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension		**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension
Línea 26:		Línea 26:
	*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)		*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)

	==Disposition ==		==Disposition==
	*Annual Screening for colon cancer in patients with concomitant [[ulcerative colitis]]		*Annual Screening for colon cancer in patients with concomitant [[ulcerative colitis]]

	==See Also ==		==See Also==

	==References==		==References==

Rossdonaldson1: Text replacement - "HTN" to "hypertension"

2016-07-31T03:00:37Z

Text replacement - "HTN" to "hypertension"

← Revisión anterior		Revisión del 03:00 31 jul 2016
Línea 22:		Línea 22:
	==Treatment ==		==Treatment ==
	*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day		*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day
	**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal ~~HTN~~		**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension
	*Periodic dilation of strictures via ERCP or percutaneous route		*Periodic dilation of strictures via ERCP or percutaneous route
	*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)		*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)